Abstract
In absence of a vaccine or antiviral drugs for the COVID-19 pandemic, it becomes urgent to test for positiveness to the virus as many people as possible, in order to detect early outbreaks of the infection. Present testing solutions are based on the extraction of RNA from patients using oropharyngeal (OP) and nasopharyngeal (NP) swabs, and then testing with real-time PCR for the presence of specific RNA filaments identifying the virus. This approach is limited by the availability of reactants, trained technicians and laboratories. To speed up the testing procedures, some attempts have been done on group testing, which means that the swabs of multiple patients are grouped together and tested. Here we propose to use this technique in conjunction with a combinatorial replication scheme in which each patient is allocated in two or more groups to reduce total numbers of tests and to allow testing of even larger numbers of people. Under mild assumptions, a 13× average reduction of tests can be achieved.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
-
Funding Statement
The work of Mario R. Guarracino was prepared within the framework of the Basic Research Program at the National Research University Higher School of Economics (HSE). The results of Mario R. Guarracino were obtained with the support of the RFFI grant.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available from other studies or websites, i.e. worldometers.info
